Transmyocardial laser revascularization: from randomized trials to clinical practice. A review of techniques, evidence-based outcomes, and future directions.
Cardiac surgeons are increasingly faced with a more complex patient who has developed a pattern of diffuse coronary artery disease that cannot be completely revascularized by CAGB alone. Considering the increased operative and long-term cardiac risks predicted by incomplete revascularization, and the documented operative and long-term benefits associated with sole therapy and adjunctive TMR in randomized patients with diffuse coronary artery disease, increased use of sole therapy and adjunctive TMR therapy is warranted.
Allen
Keith B
KB
Department of Cardiothoracic Surgery, Mid America Heart Institute, St. Luke's Hospital, 4320 Wornall Road, Suite 50, Kansas City, MO 64111, USA. kallen2340@aol.com
Kelly
James
J
Borkon
A Michael
AM
Stuart
R Scott
RS
Daon
Emmanuel
E
Pak
Alexander F
AF
Zorn
George L
GL
Haines
Michelle
M